In combination with our work on dapagliflozin, the positive results demonstrate that SGLT2 inhibitors are beneficial for decreasing arterial wall stiffness in patients with type 2 diabetes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.